BiotechTube
Home/Pipeline/Immuron CDI Candidate

Immuron CDI Candidate

Clostridioides difficile infection

Phase 2Active

Key Facts

Indication
Clostridioides difficile infection
Phase
Phase 2
Status
Active
Company
Immuron

About Immuron

Australian biotech delivering oral polyclonal antibodies from bovine colostrum for GI disease prevention and treatment.

View full company profile

Therapeutic Areas

GastrointestinalInfectious Diseases

Other Clostridioides difficile infection Drugs

DrugCompanyPhase
C. diff Clinical TrialsPanThera BioNot Specified